Editors Overview

tdd maintains an Editorial Board of practicing researchers from around the world, to ensure manuscripts are handled by editors who are experts in the field of study.

Open Access
Special Issue
Topic

Current and Future perspectives on Drug-Device combination products for Autoimmune diseases drug delivery and their clinical application

Abstract Submission Deadline : November 30, 2024

Manuscript Submission Deadline : December 25, 2024

Special Issue Description

When the body’s natural defense system can’t distinguish between your cells and alien cells, it develops an autoimmune illness and unintentionally attacks healthy cells. Autoimmune illnesses come in more than 80 different varieties and affect many different body parts. Autoimmune medications like Prednisone, methylprednisolone, dexamethasone · Colchicine · Hydroxychloroquine (Plaquenil) · Sulfasalazine, which frequently have dose-dependent side effects, must be used over an extended period to treat inflammatory illnesses. Several devices have been released on the market or are in development over the years as a result of extensive research on local drug delivery methods to decrease their off-target negative effects and treatment frequency. There are still many obstacles to overcome, and some uses for drug delivery technologies are underutilized. This review highlights local drug delivery methods in several inflammatory illnesses, including applications with untapped potential and targets that are well-known to drug delivery scientists (such as joints, eyes, and teeth) (e.g., sinus, bladder, and colon).

Keywords

Combination products, Autoimmune disease, Pharmaceutical device, Injectable formulations

Manuscript Submission information

Manuscripts should be submitted online via the manuscript Engine. Once you register on APID, click here to go to the submission form. Manuscripts can be submitted until the deadline.
All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the email address:[email protected] for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a Double-blind peer-review process. A guide for authors and other relevant information for the submission of manuscripts is available on the Instructions for Authors page.

Participating journals:


2394-7268

Journal Name

Trends in Drug Delivery

Abbrivation


tdd

ISSN


2394-7268

Since

2014

APC

950  $